![Cameron Turtle](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 49 M $ al 31/05/2026
Cameron Turtle is currently Chief Executive Officer & Director at Spyre Therapeutics, Inc. since 2023.
Dr. Turtle is also Director at CoA Therapeutics, Inc. since 2018, Director at Fortify Therapeutics, Inc. since 2017, Director at Dermecular Therapeutics, Inc. since 2017, Director at Aspa Therapeutics, Inc. since 2018, and Independent Director at Damora Therapeutics, Inc. starting in 2026.
Former roles include Independent Director at Oruka Therapeutics, Inc. from 2024 to 2025, Chief Business Officer at Eidos Therapeutics, Inc. from 2018 to 2021, VP-Business Development & Operations at Navire Pharma, Inc. from 2017 to 2018, Venture Partner at Foresite Labs LLC from 2022 to 2023, and Chief Strategy Officer at BridgeBio Pharma, Inc. from 2021 to 2022.
Education includes undergraduate studies at the University of Washington and a doctorate from St. John's College.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
SPYRE THERAPEUTICS, INC 0,69 % | 01/06/2026 | 597.540 ( 0,69 % ) | 44 M $ | 31/05/2026 |
0,18 % | 02/06/2025 | 85.233 ( 0,18 % ) | 5 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| SPYRE THERAPEUTICS, INC. | Director Ejecutivo | 27/11/2023 |
| DAMORA THERAPEUTICS, INC. | Director/Miembro de la Junta | 23/03/2026 |
Aspa Therapeutics, Inc.
 Aspa Therapeutics, Inc. Aerospace & DefenseElectronic Technology Part of BridgeBio Pharma, Inc., Aspa Therapeutics, Inc. is a biotechnology company focused on developing gene therapy for Canavan disease, a rare genetic leukodystrophy caused by mutations in the ASPA gene. The company is based in San Francisco, CA. The disease leads to toxic accumulation of N-acetyl-L-aspartic acid in the brain, resulting in demyelination and severe neurological impairment. Aspa Therapeutics is conducting the CanAspire clinical trial to evaluate an adeno-associated virus (AAV) gene therapy designed to deliver functional ASPA genes to the brain and address the root cause of the disease. The therapy was developed in collaboration with the University of Massachusetts Medical School. The company collaborates with patient advocacy organizations and provides resources and updates to patients and families. | Director/Miembro de la Junta | 01/06/2018 |
CoA Therapeutics, Inc.
 CoA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Director/Miembro de la Junta | 01/01/2018 |
Dermecular Therapeutics, Inc. | Director/Miembro de la Junta | 01/07/2017 |
Fortify Therapeutics, Inc.
 Fortify Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Director/Miembro de la Junta | 01/12/2017 |
| Empresas | Cargo | Fin |
|---|---|---|
Foresite Labs LLC
 Foresite Labs LLC Miscellaneous Commercial ServicesCommercial Services Provides incubation platform services | Corporate Officer/Principal | 01/05/2023 |
| BRIDGEBIO PHARMA, INC. | Corporate Officer/Principal | 01/04/2022 |
Navire Pharma, Inc.
 Navire Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Director de Operaciones | 01/03/2018 |
| ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░ ░░░░░ | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 12 |
|---|---|
Spyre Therapeutics, Inc.
 Spyre Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biotechnology company | Health Technology |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
St. John's College
 St. John's College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Eidos Therapeutics, Inc.
 Eidos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
Navire Pharma, Inc.
Navire Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Health Technology |
CoA Therapeutics, Inc.
CoA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Health Technology |
Fortify Therapeutics, Inc.
Fortify Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Health Technology |
BridgeBio Pharma, Inc.
 BridgeBio Pharma, Inc. BiotechnologyHealth Technology Develops medicines for genetic diseases to patients | Health Technology |
Galecto, Inc.
 Galecto, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of severe diseases | Health Technology |
Dermecular Therapeutics, Inc. | |
Aspa Therapeutics, Inc.
Aspa Therapeutics, Inc. Aerospace & DefenseElectronic Technology Part of BridgeBio Pharma, Inc., Aspa Therapeutics, Inc. is a biotechnology company focused on developing gene therapy for Canavan disease, a rare genetic leukodystrophy caused by mutations in the ASPA gene. The company is based in San Francisco, CA. The disease leads to toxic accumulation of N-acetyl-L-aspartic acid in the brain, resulting in demyelination and severe neurological impairment. Aspa Therapeutics is conducting the CanAspire clinical trial to evaluate an adeno-associated virus (AAV) gene therapy designed to deliver functional ASPA genes to the brain and address the root cause of the disease. The therapy was developed in collaboration with the University of Massachusetts Medical School. The company collaborates with patient advocacy organizations and provides resources and updates to patients and families. | Electronic Technology |
Foresite Labs LLC
Foresite Labs LLC Miscellaneous Commercial ServicesCommercial Services Provides incubation platform services | Commercial Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
